Literature DB >> 21865413

Application of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Spanish cohort of patients with clinically isolated syndromes.

M Gómez-Moreno1, M Díaz-Sánchez, A Ramos-González.   

Abstract

BACKGROUND: Recently the International Panel on Diagnosis of Multiple Sclerosis (MS) has proposed new magnetic resonance imaging (MRI) criteria for the diagnosis of MS in patients with clinically isolated syndromes (CIS). We aimed to evaluate the accuracy of these new criteria for lesions dissemination in space (DIS) and time (DIT), from a single MRI scan, to predict conversion from CIS to clinically definite MS.
METHODS: We studied 67 CIS patients with baseline MRI performed within the first 3 months after onset. The follow-up was of at least 24 months. The sensitivity, specificity and accuracy of Barkhof-Tintoré criteria and the new proposed MRI criteria for DIS and DIT were calculated with SPSS v.15.0.
RESULTS: The mean age for clinical onset was 30 years and 64% of patients were female. The overall conversion rate was 74%. In our cohort, Barkhof-Tintoré criteria showed a sensitivity of 71.43%, a specificity of 66.67%, with an accuracy of 73.1%. New DIS criteria showed a sensitivity of 85.71%, a specificity of 64.71% and an accuracy of 80.30%. We also evaluated the new DIT criteria with a single MRI scan in 54 patients with baseline scans that included gadolinium-enhanced images. The sensitivity of the test was 52.63% with a specificity of 75.00% and an accuracy of 59.26%.
CONCLUSION: New DIS criteria are simpler and more sensitive than previous criteria. The sensitivity of DIT criterion using a single MRI scan was rather low, as other previous studies showed, reflecting its stringency, but it could improve the accuracy of early MS diagnosis in that group of patients with typical CIS and gadolinium-enhancing and non-enhancing lesions on their baseline scans. These results reinforce their use in MS diagnosis.

Entities:  

Mesh:

Year:  2011        PMID: 21865413     DOI: 10.1177/1352458511417828

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

1.  High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.

Authors:  Simon Gamraoui; Guillaume Mathey; Marc Debouverie; Catherine Malaplate; René Anxionnat; Francis Guillemin; Jonathan Epstein
Journal:  J Neurol       Date:  2019-02-01       Impact factor: 4.849

2.  Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI.

Authors:  F X Aymerich; C Auger; P Alcaide-Leon; D Pareto; E Huerga; J F Corral; R Mitjana; J Sastre-Garriga; X Montalban; A Rovira
Journal:  Eur Radiol       Date:  2016-07-25       Impact factor: 5.315

3.  Should the symptomatic region be included in dissemination in space in MRI criteria for MS?

Authors:  Wallace J Brownlee; Josephine K Swanton; Katherine A Miszkiel; David H Miller; Olga Ciccarelli
Journal:  Neurology       Date:  2016-07-15       Impact factor: 9.910

Review 4.  [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Authors:  O Aktas; M P Wattjes; M Stangel; H-P Hartung
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

5.  Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome.

Authors:  Roos M van der Vuurst de Vries; Julia Y Mescheriakova; Yu Yi M Wong; Tessel F Runia; Naghmeh Jafari; Johnny P Samijn; Janet W K de Beukelaar; Beatrijs H A Wokke; Theodora A M Siepman; Rogier Q Hintzen
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

Review 6.  The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.

Authors:  Pascal Sati; Jiwon Oh; R Todd Constable; Nikos Evangelou; Charles R G Guttmann; Roland G Henry; Eric C Klawiter; Caterina Mainero; Luca Massacesi; Henry McFarland; Flavia Nelson; Daniel Ontaneda; Alexander Rauscher; William D Rooney; Amal P R Samaraweera; Russell T Shinohara; Raymond A Sobel; Andrew J Solomon; Constantina A Treaba; Jens Wuerfel; Robert Zivadinov; Nancy L Sicotte; Daniel Pelletier; Daniel S Reich
Journal:  Nat Rev Neurol       Date:  2016-11-11       Impact factor: 42.937

7.  Optimizing multiple sclerosis diagnosis: gene expression and genomic association.

Authors:  Michael Gurevich; Gadi Miron; Anat Achiron
Journal:  Ann Clin Transl Neurol       Date:  2015-02-06       Impact factor: 4.511

8.  Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring.

Authors:  Anthony Traboulsee; Laurent Létourneau-Guillon; Mark Steven Freedman; Paul W O'Connor; Aditya Bharatha; Santanu Chakraborty; J Marc Girard; Fabrizio Giuliani; John T Lysack; James J Marriott; Luanne M Metz; Sarah A Morrow; Jiwon Oh; Manas Sharma; Robert A Vandorpe; Talia Alexandra Vertinsky; Vikram S Wadhwa; Sarah von Riedemann; David K B Li
Journal:  Can J Neurol Sci       Date:  2015-04-21       Impact factor: 2.104

Review 9.  Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.

Authors:  Amy M Lavery; Leonard H Verhey; Amy T Waldman
Journal:  Mult Scler Int       Date:  2014-05-04

10.  Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria.

Authors:  R Alroughani; J Al Hashel; S Lamdhade; S F Ahmed
Journal:  ISRN Neurol       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.